Abstract
In the era of chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a new analysis from the Center for International Blood & Marrow Transplant Research (CIBMTR) confirms an ongoing role for autologous transplant in patients with chemosensitive relapsed DLBCL.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
